Alpha 2.0
Login Register
» Authors » Linda P T Joosten

Linda P T Joosten

Explore the profile of Linda P T Joosten including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 55
Followers 0
Related Specialties
General Medicine
Cardiology & Vascular Diseases
Science
Top 10 Co-Authors
Frans H Rutten
Geert-Jan Geersing
Sander van Doorn
Martin E W Hemels
Menno V Huisman
Arno W Hoes
Melchior C Nierman
Maarten van Smeden
Huiberdina L Koek
Kit C Roes
Published In
Ann Intern Med
PLoS One
Ned Tijdschr Geneeskd
BMJ Open
Open Heart
Affiliations
Soon will be listed here.
Recent Articles
1.
[Coumarin or DOAC in frail elderly patients with atrial fibrillation?]
Joosten L, van Doorn S, Hemels M, Huisman M, Rutten F, Geersing G
Ned Tijdschr Geneeskd . 2024 Mar; 168. PMID: 38525862
Objective: To investigate whether frail elderly people with atrial fibrillation (AF) who are currently using a vitamin K antagonist (VKA) should be switched to a direct-acting oral anticoagulant (DOAC). Design:...
2.
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
Joosten L, van Doorn S, van de Ven P, Kohlen B, Nierman M, Koek H, et al.
Circulation . 2023 Aug; 149(4):279-289. PMID: 37634130
Background: There is ambiguity whether frail patients with atrial fibrillation managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC). Methods: We conducted a...
3.
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
Joosten L, van Maanen R, van den Dries C, Rutten F, Hoes A, Granger C, et al.
Open Heart . 2023 May; 10(1). PMID: 37169490
Objective: Postmarketing observational studies report that a substantial percentage of patients with atrial fibrillation (AF) receive a reduced non-vitamin K antagonist oral anticoagulant (NOAC) dose without a clear indication. Recently,...
4.
Cardiovascular vulnerability predicts hospitalisation in primary care clinically suspected and confirmed COVID-19 patients: A model development and validation study
van Royen F, Joosten L, van Smeden M, Slottje P, Rutten F, Geersing G, et al.
PLoS One . 2022 Apr; 17(4):e0266750. PMID: 35404964
Objectives: Cardiovascular conditions were shown to be predictive of clinical deterioration in hospitalised patients with coronavirus disease 2019 (COVID-19). Whether this also holds for outpatients managed in primary care is...
5.
Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients
Offerhaus J, Joosten L, van Smeden M, Linschoten M, Bleijendaal H, Tieleman R, et al.
Int J Cardiol Heart Vasc . 2022 Feb; 39:100970. PMID: 35136831
Background: Coronavirus disease 2019 (COVID-19) is a systemic disease with cardiovascular involvement, including cardiac arrhythmias. Notably, new-onset atrial fibrillation (AF) and atrial flutter (AFL) during hospitalisation in COVID-19 patients has...
6.
Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
Joosten L, van Doorn S, Hoes A, Nierman M, Wiersma N, Koek H, et al.
BMJ Open . 2020 Jan; 9(12):e032488. PMID: 31888928
Introduction: Clinical guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF). Frail elderly were under-represented in...
7.
Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation
Joosten L, van Doorn S, Rutten F, Geersing G
Ann Intern Med . 2019 Jun; 170(11):816-817. PMID: 31158860
No abstract available.